Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.

Rubio-Herrera, Miguel A; Mera-Carreiro, Sara; Sánchez-Pernaute, Andrés; Ramos-Levi, Ana M

Rubio-Herrera, Miguel A; Mera-Carreiro, Sara; Sánchez-Pernaute, Andrés; Ramos-Levi, Ana M.

Afiliação

Rubio-Herrera MA; Departament of Endocrinology and Nutrition, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Mera-Carreiro S; Department of Medicine, Faculty of Medicine, Universidad Complutense, 28040 Madrid, Spain.
Sánchez-Pernaute A; Departament of Endocrinology and Nutrition, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Ramos-Levi AM; Department of Surgery, Hospital Clínico San Carlos (IdISSC), Faculty of Medicine, Department of Surgery, Universidad Complutense, 28040 Madrid, Spain.

Biomedicines ; 11(10)2023 Oct 13.

Article em En | MEDLINE | ID: mdl-37893158

Palavras-chave

bariatric surgery; liraglutide; semaglutide; severe obesity; waiting list

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Biomedicines Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google